scispace - formally typeset
Book ChapterDOI

Protein-Protein Interfaces and Diseases

Pandjassarame Kangueane, +1 more
- pp 179-187
TLDR
This work illustrates and discusses the phenomenon of subunit-subunit interfaces in protein-protein complexes using a hexameric (six subunits) cholera toxin (CT) and a HIV-1/ENV GP160 (GP120/GP40) trimer (three subunits).
Abstract
A number of protein-protein complexes are associated with disease progression and are considered as targets for drug and vaccine development. Therefore, it is important to understand protein-protein interfaces in these disease-linked complexes. We illustrate and discuss this phenomenon using a hexameric (six subunits) cholera toxin (CT) and a HIV-1/ENV GP160 (GP120/GP40) trimer (three subunits) spike protein complex. Analysis of subunit-subunit interfaces in these complexes play an important role in the design, development, and production of a stable yet a viable vaccine.

read more

References
More filters
Journal ArticleDOI

Novel computer program for fast exact calculation of accessible and molecular surface areas and average surface curvature.

TL;DR: Fast, memory‐efficient and robust execution make this software attractive for applications both in computationally expensive energy minimization algorithms, such as docking or molecular dynamics simulations, and in stand‐alone surface area and curvature calculations.
Journal ArticleDOI

Structural inferences for Cholera toxin mutations in Vibrio cholerae.

TL;DR: In this article, the authors locate the position of these mutations in the AB5 structure to infer complex assembly for its functional role in different serogroups and show that mutations in CTA are at the solvent exposed regions of AB5 complex, whereas those in the CTB/CTB interface of the homo-pentamer complex.
Journal ArticleDOI

HIV-1 envelope accessible surface and polarity: clade, blood, and brain.

TL;DR: Regression analysis shows that blood and brain gp120 and gp41 percent sequence polarity range correlate with mean Shannon entropy, which point to the use of protein modifications to enhance HIV-1 ENV vaccines across multiple clades, blood, and brain.
Related Papers (5)